Home > Cardiology > AHA 2020 > CVD Risk Reduction > Clever trial design gets patients back on statins: the SAMSON trial

Clever trial design gets patients back on statins: the SAMSON trial

Presented By
Dr James Howard, Imperial College London, UK
Conference
AHA 2020
Trial
SAMSON

[audio mp3="https://conferences.medicom-publishers.com/wp-content/uploads/2021/02/Howard-J-et-al.-A-Three-Arm-N-of-1-Trial-With-Statin-Placebo-and-Tablet-Free.mp3"][/audio]

 

For patients who had discontinued statin therapy due to side effects, 90% of the symptom burden elicited by a statin challenge was also elicited by placebo [1]. This convinced half of the study subjects to (successfully) restart statin therapy, according to results from the SAMSON trial.

Dr James Howard (Imperial College London, UK) presented the trial data, which were simultaneously published in the New England Journal of Medicine [1,2]. The highly anticipated SAMSON trial had a very original design. “This trial was designed to clarify the mystery as to why so many of our patients suffer side effects while taking statins, and yet randomised controlled trials including placebo show a similar risk of side effects, whether patients take statin or placebo tabl...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on